OBJECTIVES: Oseltamivir has been stockpiled for emerging threat by new influenza pandemic. Recent studies report somewhat possibility of the virus emerging resistant to oseltamivir. The purpose of this study is to evaluate the cost-effectiveness of oseltamivir for influenza in Japan with considering the complications and the emergence of oseltamivir-resistant virus. METHODS: A cost-effectiveness analysis was performed by decision tree using evidence from the Japanese clinical trial and the NICE, UK, systematic reviews. The decision tree models a patient presenting with influenza likely illness and facing the alternative treatments: rapid diagnostic testing followed by treatment with oseltamivir or a comparator which goes with conventional treatments. The decision tree visualized morbidity and mortality with complications such as ill states needed for antibiotics and hospitalization due to pneumonia. The analysis included assessment of not only direct medical costs but also productivity loss. Costs were derived from published literature and the statistics in DPC (Diagnosis Procedure Combination) system in Japan. RESULTS: Considering the productivity loss during influenza and complications, oseltamivir cost JPY150,703, and the comparator, JPY163,415 per QALY. When the prevalence was in the low range of 10% through 40%, the dominance of oseltamivir vanished. The incremental cost-effectiveness ratio (ICER) of oseltamivir versus comparator was JPY398,571 per QALY. Considering the productivity loss, however, the ICER for oseltamivir turned to be negative, simple dominant, JPY-2,345,714 per QALY. Regarding the virus emerging resistant to the drug, we found the dominance of oseltamivir vanish if the emerging rate becomes more than 27%. Sensitivity analysis also suggested that the emerging rate of the drug-resistant virus was more sensitive in the influenza peri-season (prevalence: 40-60%). CONCLUSION: The use of oseltamivir for influenza was so far recommended as cost-effectiveness in Japan. However, the advantage of oseltamivir is affected by both the prevalence and emerging rate of the oseltamivir-resistant virus.
for Germany, the cost-effectiveness of a candidate prophylactic cervical cancer vaccine with potential cross-protection benefits. METHODS: A Markov model based upon the natural history of HPV and cervical cancer was developed to simulate transitions between health states: Normal, HPV, Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer (CC) stages 1 to 4, and death. Using a lifetime simulation of 12-year old girls, the model was adapted for country-specific epidemiological data: age-specific HPV prevalence, HPV type distribution in cervical disease, prevalence of pre-cancerous lesions, and age-specific CC incidence and mortality. Country-specific screening practices and costs were used with a discount rate of 4% on costs, 1.5% on outcomes. Published efficacy rates were used for the candidate vaccine including a potential cross-protection benefit (i.e., additional efficacy against oncogenic HPV types 31 and 45). Sensitivity analyses were performed on costs, discount rates, efficacies, cross-protection, and age at vaccination. RESULTS: Reductions in CC and related deaths were predicted to be 81% (80% mortality) following vaccination of 12 year old girls. The corresponding cost per life-year gained ranged from €19,600 to €20,700 respectively, depending upon whether the analysis was conducted from a societal or health-care payer perspective. When considering quality of life benefits, the vaccine showed a cost per qualityadjusted life-year of €14,700 (societal) to €15,500 (payer). Results were most sensitive to assumptions about discount rates and age at vaccination. For cohorts of 18, and 25-year-old women, vaccination has estimated cost per QALYs of €16,100 and €18,800 (societal), and €15,300 and €18,000 (payer), respectively. CONCLUSION: Prophylactic vaccination against CC with a candidate HPV 16/18 vaccine is a cost-effective method of reducing precancerous cervical lesions, cervical cancer incidence and mortality in Germany.
PIN20 COST EFFECTIVENESS ANALYSIS OF BRIVUDINE COMPARED WITH ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN SPAIN
Darba J 1 , Restovic G 2 1 Universitat de Barcelona, Barcelona, Spain, 2 BCN Health Economics & Outcomes Research, Barcelona, Spain OBJECTIVES: This study estimates the cost and the effectiveness of brivudine and aciclovir in the treatment of Herpes Zoster (HZ) in Spain focusing on the number of post herpetic neuralgia (PHN) avoided cases. METHODS: A cost-effectiveness decision model was built from clinical results obtained in the double-blind controlled trail that compared brivudine and aciclovir. The analytic model estimates the mean cost per patient treated with HZ and the mean cost per PHN avoided case. Time horizon of the study considered HZ acute treatment period (7 days) plus PHN treatment period (between 90 and 180 days). This decision model also considers the incidence rate of HZ in Spain for patients older than 50 years, clinical drug effectiveness, HZ and PHN direct medical costs and three PHN treatments options (tramadol, gabapentine and pregabaline). RESULTS: It has been estimated that 109.982 patients with HZ would be treated in Spain each year. If all those patients would be treated with brivudine, then 8,976 NPH cases could be avoided if the same number of patients would receive aciclovir. Mean cost per treated patient would be lower with brivudine for all PHN treatment options. Overall, brivudine has a greater effectiveness and a lower cost per treated patient, thus estimated direct medical cost per PHN avoided case would be reduced in 33€ when the PHN patient is treated with tramadol, 35€ for gabapentine and 71€ for pregabaline. CONCLUSION: Results from base-case and sensi-Abstracts A441
